Taro’s tavaborole gets tentative FDA OK

The FDA has granted tentative approval to Taro Pharmaceutical Industries’ (NYSE:TARO) tavaborole, the generic active ingredient in Kerydin (by Novartis (NYSE:NVS) and Pfizer (NYSE:PFE)).

Perrigo (NYSE:PRGO) had confirmed it filed a paragraph IV certification on July 9, and Anacor Pharmaceuticals launched patent litigation last fall asserting patents listed in the Orange Book for Kerydin.

After hours: NVS -0.2%; PFE -0.2%.

https://seekingalpha.com/news/3521393-taros-tavaborole-gets-tentative-fda-ok